Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Hope Rugo

Breast Oncology · City of Hope

View

Dr. Virginia Borges

Breast Oncology · CU Anschutz Medical Campus

View

Dr. William Gradishar

Breast Oncology · NU

View

Dr. Jame Abraham

Breast Oncology · Cleveland Clinic

View

Dr. Azka Ali

Breast Oncology · Cleveland Clinic Lerner

View

Dr. Amy Comander

Breast Oncology · PHS

View

Dr. Paolo Tarantino

Breast Oncology · Dana-Farber Cancer Institute

View

Dr. Anastasia Martynova

Breast Oncology · USC

View

Dr. Rani Bansal

Breast Oncology · Duke

View

Dr. Gilbert Bader

Breast Oncology · OSUMC

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    The American Joint Committee on Cancer (AJCC) Breast Cancer Staging, Eighth Edition, is more Reflective of Cancer Biology than the Seventh Edition.

    Feb 7, 2025DOI: 10.1245/s10434-025-16889-7Journal ArticleASO

    Written by: Jessica YoungMariko AsaokaFarhad GhasemiKohei ChidaArya Mariam RoyLi YanKenichi HakamadaKazuaki Takabe

    Find these authors on Roon

    AR
    Dr. Arya Roy
    Breast Oncology · OSUMC

    Summary

    BACKGROUND: The American Joint Committee on Cancer (AJCC) eighth-edition breast cancer staging system incorporating tumor grade, hormone/human epidermal growth factor receptor 2 (HER2) receptor status, and genomic assays has demonstrated better prognostic value than the seventh edition. Given the crucial role of cancer biology in prognosis, the authors hypothesized that the AJCC eighth-edition criteria offer better biologic differentiation between stages than the seventh edition.METHODS: This study analyzed 696 breast cancer patients from The Cancer Genome Atlas (TCGA) and Text Information Extraction System (TIES) database, with complete information available for staging according to both the AJCC seventh- and eighth-edition criteria.RESULTS: The study indicated an increase in the number of patients classified as stage I in the eighth edition compared with the seventh edition, particularly in hormone-positive breast cancers. Furthermore, the eighth edition demonstrated improved discrimination in overall survival between stages I and II cancers. The eighth edition was able to distinguish significant differences in cell proliferation, intratumor heterogeneity, homologous recombination deficiency, and neoantigen load between stages I and II cancers. Moreover, the eighth edition more clearly differentiated immune cell infiltration between stages II and I cancer than the seventh edition. Finally, immune activity and gene expression of immune checkpoints such as PDCD1, PDL1, CTLA4, LAG3, TIGIT, and IDO1 and 2 showed a more pronounced difference between stages I and II cancers in the eighth edition than in the seventh edition.CONCLUSION: The AJCC eighth edition breast cancer staging system better distinguishes cancers with more aggressive biology than the seventh edition.
    ARDr. Arya Roy

    Dr. Arya Roy

    Hematology & Oncology · Breast Oncology
    The Ohio State University Wexner Medical Center
    draryaroy
    Columbus, Ohio